If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
DIABETES
ISSN 2054-6181 Vol 4.1 • October 2016 • emjreviews.com
INSIDE
Review of
EASD 2016
Munich, Germany
CONTENTS
EDITORIAL BOARD...................................................................................................................................... 4
CONGRESS REVIEW.................................................................................................................................... 12
• Review of the 52nd European Association for the Study of Diabetes (EASD)
Annual Meeting, held in Munich, Germany, 12th–16th September 2016
INTERVIEWS WITH EMJ DIABETES EDITORIAL BOARD.................................................................... 29
SYMPOSIUM REVIEW
• TYPE 2 DIABETES MELLITUS: BEYOND THE BETA CELL...............................................
DIABETES ISSN 2054-6181
CONTENTS EDITORIAL BOARD.......................
DIABETES • TREATMENT OF TYPE 2 DIABETES WITH BI
Editorial Board Editor-in-Chief: Prof Jörg Hube
Diabetes Mrs Deirdre Kyne-Grzebalski, Treasur
DIABETES 4.1 OCTOBER 2016 Director Spencer Gore
Welcome Welcome to the 2016 publication of EMJ
Atherogenic Dyslipidaemia is a major cause of mor
Foreword
SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube
x E clusive Interviews from the European
12 DIABETES • October 2016
DIABETES • October 2016
EASD 2016 for this year was the introductio
Congress Highlights Interactions Bet
premature to suggest public health measures shoul
These findings suggest that social supportive care
and thus reduce compliance with this dieting stra
We would not necessarily recommend cutting these
Compared with the standard diet, the HFHS di
Although VAT volume was higher in the AAS subgrou
Preconception and Gestational Diabetes Both Linke
Our findings suggest seasonal variations in the 2-
showed a J-shaped relationship between the length
Commenting on their study, the authors stated: “I
These simulated outcomes provide patients and cli
The authors of the study, led by Dr Pavel Škrha,
FORXIGA®: A highly selective SGLT2 inhibitor
Jörg Huber Professor of Health Sciences and Depu
diabetes and other long-term conditio
Henning Beck-Nielsen Professor and Chief Physici
on insulin resistance in skeletal muscles.
Q: Have you noticed any trends in the prevalence
the tantalising question of what the environmenta
hence also more targeted treatment. The
TYPE 2 DIABETES MELLITUS: BEYOND THE BETA CELL T
tissue into brown fat, mimicking physiological ef
disease of chronic hyperglycaemia; a high glucose
Event rates for macrovascular complications
with T2DM. The EMPA-REG outcome study d
Combination Therapy in Type 2 Diabetes Mellitus:
development of personalised approaches for the tr
Decreased incretin effect GLP-1 RA, AGI Impaired
the audience responded that pancreatitis was a ma
With the range of therapies now on offer and the
trial. Expert Opin Pharmacother. 2013; 14(18)
Click here to view the AWARD WINNERS at the 5
Abstract Reviews AEROBIC PLUS RESIST
EASD 2016 6. Tock L et al. Nonalcoholic fatty li
Abstract Reviews evaluated for fasting blo
EASD 2016 myocardial infarction (MI) and stroke.
Abstract Reviews Hence, the potential to reduce
EASD 2016 expression levels of many cytokines in
Abstract Reviews obesity-induced secretory dysfu
EASD 2016 higher N-terminal pro b-type natriuret
Abstract Reviews and markedly inhibits str
EASD 2016 Blood Glucose Gluconeogenesis Pyruvat
Abstract Reviews was abrogated in Hep-Glud1-/
EASD 2016 obese group. In both groups, the incre
Abstract Reviews observed that ERK7 expression i
EASD 2016 singular validated adherence rating of
Abstract Reviews the study were 372 patients wit
EASD 2016 Annual Meeting, 12-16 September, 2016.
Abstract Reviews Table 1: Change in weight, glyca
EASD 2016 NEWLY DIAGNOSED AND PREVALENT T
EDITOR’S PICK Dr B
and wrist,2 and this association was found to be
a receptor independent of the ‘classic’ cAM
Table 1: Newest three classes of anti-hyperglycae
SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS C
(1,25-[OH] D) cannot be predicted a priori, becau
metabolism and bone density in patients with type
57. List JF et al. Sodium-glucose Di
TREATMENT OF TYPE 2 DIABETES WITH BIPHASI
long-acting insulin is added to OAD agents which
A 12 10 Glucose infusion rate (mg/kg/min) 30/7
using BIA and provides both basal and prandial co
relatively low.34 Clinical and economic outcomes
Table 1: Data from selected clinical trials invol
and individualisation is therefore essential for
The enhanced flexibility and convenience improves
Pract. 2006;12(Suppl 1):63-6. 13. Monnier L, Cole
diabetes mellitus. Diabetes Technol Ther. 2003;5(
UTILITY OF GLYCATED HAEMOGLOBIN IN GESTATIONAL
there is no uniform or best way to diagnose GDM t
groups of the proteins through the non-enzymatic
recommendations of its utility in the diagn
In our study of 607 patients in 2012, the values
6.2% for HbA1c levels <5% to 18.3% for HbA1c leve
the diagnosis and classification of hyperg
TREATMENT STRATEGIES FOR CHORIORETINAL VASC
retinal ischaemia causes profound vision los
Examination, treatment, diagnosis YesEligible for
-0.8 letters (mean number of injections: afliberce
oedema. Based on a pre-planned sub-analysis,
This has reassured surgeons and encouraged the us
are lengthened, their central retinal thickn
label extension trial of ranibizumab for choroida
ANTI-HYPERGLYCAEMIC AND LIPID PROFILE REGU
It is known that the treatment of these diseases
Table 1: Changes in the levels of fasting blood g
Table 2: Percentage changes in the biochemical pa
FBG HbA1c TG TC LDLc HDLc 60
After the basic dietary incorporation, the levels
supplementation of MOLP have positive blood
UPCOMING EVENTS Swiss Society of Endocrinology an
DIABETES Diabetes UK Professional Conference 2017
EUROPEAN MEDICAL JOURNAL provides influential ar
Buyer’s Guide • A. MENARINI DIAGNOSTICS • AB
SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NE